Search the Newsreel

Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise

Jeremy Hayden, an insider at Sight Sciences (SGHT), filed a Form 144 indicating his intent to sell 48,000 shares of common stock on August 14, 2026, following a stock option exercise. The planned sale has an aggregate market value of $395,878.84. This filing also …

Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing

Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Senti Biosciences Holdings, Inc. reported its earnings results for the second quarter and six months ended June 30, 2026. For the second quarter, the company's net loss decreased to USD 12.75 million from USD 14.73 million a year prior, with basic and diluted loss …

CORZ Stock Forecast & Analyst Ratings - August 2026

Why (ASMB) Price Action Is Critical for Tactical Trading

This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …

Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants

Baker Bros. Advisors and its related entities have disclosed a 5.2% beneficial ownership stake in IDEAYA Biosciences, Inc. (IDYA), totaling 5,010,030 shares based on 96,375,637 shares outstanding as of June 30, 2026. The firm also holds prefunded warrants with a low exercise price but …

ARK reports 9.59% stake in Pacific Biosciences (PACB)

ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over …

Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares

Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …

Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …

Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake

ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over …

Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake

Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake

Cormorant Asset Management, LP and Bihua Chen have reported a significant ownership stake of 9.17% in Bright Minds Biosciences Inc. This beneficial ownership translates to 900,000 Common Shares out of 9,812,061 shares outstanding as of May 15, 2026. The reporting persons share voting and …

Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung

TMC Life Sciences Berhad Declares First and Final Single-Tier Dividend in Respect of the Financial Year Ended 30 June 2026

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with …

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Kingfa Science & Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M

* Scienture Holdings, Inc. press release [https://seekingalpha.com/pr/20619685-scienture-reports-q2-2026-results-with-approximately-510-percent-sequential-revenue-growth] (SCNX [https://seekingalpha.com/symbol/SCNX]): Q2 Non-GAAP EPS of -$0.07. * Revenue of $0.34M. * Net loss for Q2 2026 narrowed 58% YoY to $2.82M from $6.72M in Q2 2025. * Gross profit was $0.34M with a gross margin of …

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences Corporation EW is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share. The question is whether that momentum warrants …

Scienture Holdings 2Q Loss/Shr 7c >SCNX

Scienture Holdings reported a second-quarter loss of 7 cents per share. Additionally, Unity Software reported its fourth-quarter financial results with revenue increasing 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly loss of 66 cents per share. The article provides financial data …

Will Ciena's Rising Backlog Improve Revenue Visibility Into 2027?

Ciena Corporation is experiencing strong demand and a growing backlog, which is expected to provide increased revenue visibility into fiscal 2027. The company's backlog surged to $7.7 billion in Q2 fiscal 2026, with a significant portion anticipated to convert into revenue within the next …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing a Phase III study of IFx in Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates. The company aims to address …

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

Die Thermo-Fisher-Aktie legt nach starken Quartalszahlen zu

GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …